Provided by Tiger Trade Technology Pte. Ltd.

HUTCHMED

19.770
+0.0100.05%
Volume:3.31M
Turnover:65.16M
Market Cap:17.24B
PE:4.85
High:20.080
Open:20.080
Low:19.420
Close:19.760
52wk High:28.800
52wk Low:15.570
Shares:872.00M
HK Float Shares:872.00M
Volume Ratio:0.47
T/O Rate:0.38%
Dividend:- -
Dividend Rate:- -
EPS(LYR):4.077
ROE:1.46%
ROA:-1.24%
PB:1.74
PE(LYR):4.85
PS:4.00

Loading ...

HUTCHMED (China) Ltd - Phase Trial for Sovleplenib in Waha Met Primary Endpoint in January 2026

THOMSON REUTERS
·
Apr 29

HUTCHMED (China) Ltd - Nda for Sovleplenib in Waha Accepted With Priority Review by Nmpa

THOMSON REUTERS
·
Apr 29

HUTCHMED Announces Nda Acceptance in China With Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

THOMSON REUTERS
·
Apr 29

HUTCHMED to present new HMPL-A580 preclinical data at AACR annual meeting

Reuters
·
Apr 09

HUTCHMED Introduces 10-Year Share Option Scheme with 5% Issuance Cap and Strict Governance Framework

Bulletin Express
·
Apr 09

HUTCHMED Schedules 12 May 2026 Hybrid AGM; Shareholders to Vote on FY 2025 Accounts, Board Re-elections and 2026 Share Option Scheme

Bulletin Express
·
Apr 09

HUTCHMED Sets 12 May AGM to Vote on 10 % Issue/Buy-Back Mandates and 2026 Share Option Scheme

Bulletin Express
·
Apr 09

HUTCHMED publishes sustainability report, cites 48% cut in carbon emission intensity since 2020

Reuters
·
Apr 09

HUTCHMED publishes 2025 annual report, posts $457 million net income attributable to shareholders

Reuters
·
Apr 09

HUTCHMED to Unveil First-in-Class ATTC HMPL-A580 and New Surufatinib Combination Data at AACR 2026

Bulletin Express
·
Apr 09

HUTCHMED to present Phase II surufatinib combination data in pancreatic cancer at AACR 2026

Reuters
·
Apr 09

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026

GlobeNewswire
·
Apr 09

Hong Kong Stocks Poised for Bottoming in April, Focus on AI Applications and Autonomous Driving

Stock News
·
Apr 02

HUTCHMED Records Stable Share Capital in March 2026; Public Float Fully Compliant

Bulletin Express
·
Apr 01

HUTCHMED files Form 3 for Group General Counsel Charles George Rupert Nixon

Reuters
·
Apr 01

Hutchmed Begins Blood Cancer Drug Trial

MT Newswires Live
·
Mar 23

HUTCHMED Initiates Phase III Trial in China for HMPL-760 in Relapsed/Refractory DLBCL

Stock News
·
Mar 23

HUTCHMED launches Phase III China trial of HMPL-760 plus R-GemOx in relapsed/refractory DLBCL

Reuters
·
Mar 23

HUTCHMED Initiates Phase Iii Trial of Hmpl-760 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma in China

THOMSON REUTERS
·
Mar 23

HUTCHMED (China) Ltd. files initial beneficial ownership statement for Deputy CFO Lorenso Chiu

Reuters
·
Mar 19